GLPwatch

A Real-World Study on the Impact of Weight Loss on Treatment Efficacy in Overweight/Obese Patients With Plaque Psoriasis

NCT07382388 · Not yet recruiting

Last updated 2026-05-28

This study is observing how weight loss affects the effectiveness of treatment in overweight or obese adults with plaque psoriasis over 24 weeks.

Status Not yet recruiting Approved but enrollment has not started.
Type Observational
Participants 70 people Planned (estimated).
Who can join Ages 18+ · all sexes
Timeline Started 2026-01 · est. completion 2027-12

What this study is testing ClinicalTrials.gov NCT07382388 ↗

Description as written by the study sponsor.

The goal of this investigator-initiated, real-world, observational study is to investigate the impact of weight loss on treatment efficacy in overweight or obese Chinese patients with moderate-to-severe plaque psoriasis. The main question it aims to answer is: Does a structured weight loss intervention (including dietary management, exercise, and/or pharmacotherapy) improve the clinical response to psoriasis therapy in this population, as measured by the proportion of patients achieving a Psoriasis Area and Severity Index (PASI) score below 3 at Week 24? Researchers will compare the Weight Loss Intervention Group (receiving standard psoriasis care plus a personalized weight management program) to the Control Group (receiving standard psoriasis care only) to see if the addition of weight loss strategies leads to superior improvements in psoriasis severity, metabolic parameters, and quality of life. Participants will: Receive standardized treatment for their psoriasis based on disease severity. Be allocated (based on patient preference and clinical judgment) to either the intervention or control group. In the intervention group, receive and follow a personalized weight management plan, which may include dietary counseling, a tailored exercise regimen, and/or Glucagon-Like Peptide-1(GLP-1) receptor agonist therapy (e.g., Semaglutide, Tirzepatide) if indicated. Undergo scheduled assessments at baseline, Week 12, and Week 24, including: Clinical evaluations (PASI, Physician's Global Assessment, body surface area). Anthropometric measurements (weight, BMI, waist/hip circumference). Quality of life assessment (Dermatology Life Quality Index). Safety monitoring for adverse events. To investigate the impact of weight loss on treatment efficacy among overweight/obese Chinese patients with plaque psoriasis.

Treatments tested

Main thing measuredProportion of PASI<3 at Week 24
SponsorPeking University Third Hospital
Conditions studiedPsoriasis
GLP-1 drugs

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT07382388 ↗